The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors

• Type of Material: Article
• Authors: Shannon Meeks, Emory University; Cindy A. Leissinger, Tulane University
• Language: English
• Date: 2019-09-05
• Publisher: Wiley: 12 months
• Publication Version: Final Published Version
• Copyright Statement: © 2019 The Authors.Haemophilia published by John Wiley & Sons Ltd
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1111/hae.13845
• Title of Journal or Parent Work: Haemophilia
• ISSN: 1351-8216
• Volume: 25
• Issue: 6
• Start Page: 911
• End Page: 918
• Grant/Funding Information: HEMA Biologics, LLC
• Keywords: SECONDARY PROPHYLAXIS; TISSUE FACTOR; comprehensive care; ON-DEMAND TREATMENT; personalized treatment; haemophilia; RANDOMIZED-TRIAL; RECOMBINANT FACTOR-VIIA; mechanism of action; rFVIIa; FACTOR-IX; CONGENITAL HEMOPHILIA; RFVIIA; Science & Technology; Hematology; inhibitors; HOME TREATMENT; Life Sciences & Biomedicine; DOUBLE-BLIND
• Research Categories: Health Sciences, Pharmacology; Health Sciences, Medicine and Surgery

Abstract

The use of activated factor VII (FVIIa) for the treatment of bleeding events in haemophilia patients with inhibitors was first reported over 30 years ago. Since then clinical trials, registries, case series, real-world experience and an understanding of its mechanism of action have transformed what was originally a scientific curiosity into one of the major treatments for inhibitor patients, with innovative therapeutic regimens, dose optimization and individualized care now widely practiced. Given current understanding and use, it might be easy to forget the years of clinical research that led up to this point; in this review, we lay out changes based on broad eras of rFVIIa use. These eras cover the original uncertainty associated with dosing, efficacy and safety; the transformation of care ushered in with its widespread use; and the optimization and individualization of patient care and the importance of specialized support provided by haemophilia treatment centres. Today with the introduction of novel prophylactic agents such as emicizumab, we once again find ourselves dealing with the uncertainties of how best to utilize rFVIIa and newer investigational variants such as marzeptacog alfa and eptacog beta; we hope that the experiences of the past three decades will serve as a guide for this new era of care.